Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
RESEARCH TOOLSreports
Holding BCYC?
Track your performance easily
BCYC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.17 - $28.67
Previous CloseN/A
Volume92.63K
Average Volume (3M)723.15K
Market Cap
$937.93M
Enterprise Value$681.44M
Total Cash (Recent Filing)$67.66M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 04, 2025EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.30
Shares Outstanding47,553,920
10 Day Avg. Volume368,299
30 Day Avg. Volume723,152
Standard Deviation0.18
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)25.43
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue18.47
Enterprise Value/Gross Profit25.26
Enterprise Value/Ebitda-4.24
Forecast
1Y Price Target
$31.20Price Target Upside133.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Bicycle Therapeutics News
PremiumCompany Announcements
Bicycle Therapeutics Reports Promising Trial Results and Future Plans
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe updated overall response rate of 65% in the Phase 1/2 study for zelenectide pevedotin and pembrolizumab combination in metastatic urothelial cancer is highly encouraging.
Financial PositionBicycle Therapeutics has a strong cash position of $890.9 million, contributing to a unique investment opportunity.
Partnerships And Strategic AlliancesWith the zele pivotal trial enrolling and multiple partnerships providing non-dilutive capital, Bicycle Therapeutics demonstrates strong external pipeline validation.
Bears Say
Efficacy And CompetitionThe zele pembro combo in mUC underperformed compared to competitors, with a lower confirmed objective response rate than expected.
Financial PerformanceFor 3Q24, the company reported revenues of $2.7M, compared to consensus estimate of $6.8M.
Safety And Side EffectsThe safety profile has deteriorated versus the previous update and includes an increased incidence of peripheral neuropathy.
---
Ownership Overview
23.88% Insiders
5.80% Mutual Funds
0.28% Other Institutional Investors
69.26% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCYC FAQ
What was Bicycle Therapeutics Ltd’s price range in the past 12 months?
Bicycle Therapeutics Ltd lowest stock price was $12.17 and its highest was $28.67 in the past 12 months.
What is Bicycle Therapeutics Ltd’s market cap?
Bicycle Therapeutics Ltd’s market cap is $937.93M.
When is Bicycle Therapeutics Ltd’s upcoming earnings report date?
Bicycle Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2025 which is in 41 days.
How were Bicycle Therapeutics Ltd’s earnings last quarter?
Bicycle Therapeutics Ltd released its earnings results on Oct 31, 2024. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.797 by $0.057.
Is Bicycle Therapeutics Ltd overvalued?
According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued.
Does Bicycle Therapeutics Ltd pay dividends?
Bicycle Therapeutics Ltd does not currently pay dividends.
What is Bicycle Therapeutics Ltd’s EPS estimate?
Bicycle Therapeutics Ltd’s EPS estimate is -0.86.
How many shares outstanding does Bicycle Therapeutics Ltd have?
Bicycle Therapeutics Ltd has 47,553,920 shares outstanding.
What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?
Bicycle Therapeutics Ltd reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.797. Following the earnings report the stock price went down -2.455%.
Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?
Currently, no hedge funds are holding shares in BCYC
---
Bicycle Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.20 (133.88% Upside)
$31.20 (133.88% Upside)
Blogger Sentiment
Bullish
BCYC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $507.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.78%
12-Months-Change
Fundamentals
Return on Equity
-26.82%
Trailing 12-Months
Asset Growth
56.06%
Trailing 12-Months
Company Description
Bicycle Therapeutics Ltd
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
---
BCYC Stock 12 Month Forecast
Average Price Target
$31.20
▲(133.88% Upside)
Technical Analysis
Blueprint Medicines
―
Kura Oncology
―
Adaptimmune Therapeutics
―
Meiragtx Holdings
―
RegenXBio
―
Scholar Rock Holding
―
Best Analysts Covering BCYC
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+16.68%
reiterated a buy rating 3 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +16.68% per trade.
---